|
Hello Immunization Partners,
Please share the following information with providers in your jurisdiction.
The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) met on April 15-16, 2025. ACIP approved the following recommendations by majority vote.
Meningococcal Vaccine:
ACIP voted to recommend that GSK’s MenABCWY vaccine (PENMENVY) may be used when both MenACWY and MenB are indicated at the same visit.
- Healthy persons aged 16 through 23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine.
- People aged 10 years and older who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia).
In a separate vote, ACIP voted to include the pentavalent GSK vaccine (PENMENVY) in the Vaccines for Children (VFC) program.
Respiratory Syncytial Virus (RSV):
ACIP voted to recommend that adults aged 50 through 59 years who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.
- Only applies to Arexvy (GSK) and Abrysvo (Pfizer). mResvia (Moderna) has submitted to FDA for licensure in adults ages 18 through 59 years
CDC will publish clinical considerations that describe the chronic medical conditions and other risk factors for severe RSV disease. Timing of RSV vaccination is unchanged. In most areas, vaccination is of greatest benefit when given from August to October. However, eligible adults may receive RSV vaccination year-round.
Chikungunya Vaccine:
ACIP conducted three separate votes on the use of chikungunya vaccines for travelers and laboratory workers.
Travelers:
ACIP recommended use of virus-like particle chikungunya vaccine VIMKUNYA™ (CHIK-VLP) for people aged 12 years and older traveling to a country or territory where there is a chikungunya outbreak. VIMKUNYA™ vaccine may also be considered for people aged 12 years and older traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time (e.g., 6 months or more).
ACIP recommended use of live attenuated chikungunya vaccine IXCHIQ® (CHIK-LA) for people aged 18 years and older traveling to a country or territory where there is a chikungunya outbreak. IXCHIQ® vaccine may also be considered for people aged 18 years and older traveling or taking up residence in a country or territory without an outbreak but with elevated risk for U.S. travelers if planning travel for an extended period of time (e.g., 6 months or more).
Please Note: The Michigan Department of Health and Human Services (MDHHS) Division of Immunization sent an email on May 14, 2025, to inform providers about information that was released after the April ACIP meeting regarding the use of IXCHIQ®. On May 9, 2025, the U.S. Food and Drug Administration (FDA) and the CDC are recommending a pause in the use of IXCHIQ® in individuals 60 years of age and older while they investigate post marketing reports of serious adverse events, including neurologic and cardiac events in individuals who have received the vaccine. People 60 years and older should not receive IXCHIQ® until these additional reports are further investigated.
Laboratory Workers:
ACIP recommended use of VIMKUNYA™ vaccine for laboratory workers with potential for exposure to chikungunya virus. (Note: IXCHIQ® vaccine is already recommended option for this population).
In addition to the above recommendations, ACIP had discussion surrounding several additional topics including self-administered LAIV, updated mRNA COVID-19 vaccine, new monoclonal antibody product for infant RSV prevention, mpox, HPV and CMV. For a summary of this discussion, please see Immunize.org’s IZ Express April 23, 2025 Newsletter Issue 1810.
For presentation slides and a recording of the April 2025 ACIP meeting, please visit the resources below:
ACIP Presentation Slides: April 15-16, 2025, Meeting | ACIP | CDC
YouTube Live Stream Link 4-15-2025
YouTube Live Stream Link 4-16-2025
Thank you for all you do to protect Michigan residents from vaccine preventable diseases.
The Immunization Outreach and Education Team
|
